Severe adverse reactions to combination of srotoninergic drugs;Kombination av serotonerga läkemedel gav kraftiga biverkningar

Lakartidningen

Volumn 101, Issue 18, 2004, Pages 1618-1619

  Jägestedt, Marianne ^a   Von Bahr, Christer ^b,c  

^a Stureby Vårdcentral ^*

^b STOCKHOLM SÖDER HOSPITAL   (Sweden)

^c Klinisk Farmakologi   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BUSPIRONE; CYTOCHROME P450 2D6; PAPAVERINE; PAROXETINE; SEROTONIN AGONIST; ANTIDEPRESSANT AGENT; SEROTONIN UPTAKE INHIBITOR; VASODILATOR AGENT;

ADULT; ARTICLE; CASE REPORT; DEPRESSION; DRUG FEVER; DRUG METABOLISM; ECCHYMOSIS; FEMALE; HUMAN; HYPERREFLEXIA; MUSCLE CRAMP; SHIVERING; TACHYCARDIA; TREMOR; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; DRUG INTERACTION; METABOLISM; MIDDLE AGED; SEROTONIN SYNDROME;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BUSPIRONE; CYTOCHROME P-450 CYP2D6; DEPRESSION; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MIDDLE AGED; PAPAVERINE; PAROXETINE; SEROTONIN AGONISTS; SEROTONIN SYNDROME; SEROTONIN UPTAKE INHIBITORS; VASODILATOR AGENTS;

EID: 2942617038     PISSN: 00237205     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Drugline nr 12507 (1995). http://www.janusinfo.se
2. Höjer J, Personne M, Skagius AS Hansson O. Serotoninergt syndrom. Läkartidningen 2002;99:2054-60.
3. Sternbach H. The serotonin syndrome. Am J Psychiatry 1991;148:705-13.
4. Layton D, Clark DWJ, Pearce GL. Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Eur J Clin Pharmacol 2001;57:167-76.
5. Cooper TA, Valcour VG, Gibbons RB, O'Brien-Falls K. Spontaneous ecchymoses due to paroxetine administration. Am J Med 1998;104:197-8.
6. Oksbjerg Dalton S, Johansen C, Mellemkjaer L, Nørgård B, Toft Sørensen H, Olsen JH. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding. Arch Intern Med 2003;163:59-64.
7. Drugline nr 17917 (2001). http://www.janusinfo.se
8. Läkemedelsverkets biverkningsdatabas (Swedis 2003 03 31).
9. Manos GH. Possible serotonin syndrome associated with buspirone added to fluoxetine. Ann Pharmacother 2000;34:871-4.
10. Dollery C. Therapeutic drugs. 2nd ed. Edinburgh: Churchill & Livingstone; 1997. p. 17-9.
11. ÖGAT på läkemedel 2002(111): http://www.janusinfo.org/ imcms/ servlet/GetDoc?meta_id=4075
12. Laine K, Tybring G, Härtter S, Andersson K, Svensson JO, Widén J, et al. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test. Clin Pharmacol Ther 2001;70:327-35.
13. Drugline nr 15083 (1995). http://www.janusinfo.se
14. Kivisto KT, Lamberg TS, Kantola T, Neuvonen PJ. Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole. Clin Pharmacol Ther 1997;62:348-54.
15. Lilja JJ, Kivisto KT, Backman JT, Lamberg TS, Neuvonen PJ. Grapefruit juice substantially increases plasma concentrations of buspiron. Clin Pharmacol Ther 1998;64:655-60.
16. Inaba T, Jurima M, Mahon WA, Kalow W. In vitro inhibition studies of two isozymes of human liver cytochrome P450. Mephenytoin p-hydroxylase and sparteine monooxygenase. Drug Metab Dispos 1985;13:443-8.